Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

From today's edition of Real Money:

AUPH down 30%. AUPH is a classic example of a stock with good news but not yet appreciated by the market. It made substantial progress in the development of its drug for the treatment of lupus nephritis but the market is waiting for FDA approval which is expected in late January. I believe this stock will see increased interest as the FDA decision approaches.

https://realmoney.thestreet.com/investing/my-top-six-2020-stock-picks-gained-an-average-of-75--15527044